CN100482646C - N-[苯基(哌啶-2-基)甲基]苯甲酰胺衍生物,其制备方法及其在治疗中的应用 - Google Patents

N-[苯基(哌啶-2-基)甲基]苯甲酰胺衍生物,其制备方法及其在治疗中的应用 Download PDF

Info

Publication number
CN100482646C
CN100482646C CNB038140063A CN03814006A CN100482646C CN 100482646 C CN100482646 C CN 100482646C CN B038140063 A CNB038140063 A CN B038140063A CN 03814006 A CN03814006 A CN 03814006A CN 100482646 C CN100482646 C CN 100482646C
Authority
CN
China
Prior art keywords
sub
group
methyl
phenyl
general formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB038140063A
Other languages
English (en)
Chinese (zh)
Other versions
CN1662497A (zh
Inventor
G·达加赞利
G·埃斯特尼-鲍托
P·玛加特
B·玛拉鲍特
F·梅代斯克
P·罗杰
M·瑟弗林
C·弗罗尼克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sha Nuofei Afangdi
Sanofi Aventis France
Original Assignee
Sha Nuofei Afangdi
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sha Nuofei Afangdi, Sanofi Aventis France filed Critical Sha Nuofei Afangdi
Publication of CN1662497A publication Critical patent/CN1662497A/zh
Application granted granted Critical
Publication of CN100482646C publication Critical patent/CN100482646C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CNB038140063A 2002-04-19 2003-04-17 N-[苯基(哌啶-2-基)甲基]苯甲酰胺衍生物,其制备方法及其在治疗中的应用 Expired - Fee Related CN100482646C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR02/04916 2002-04-19
FR0204916A FR2838739B1 (fr) 2002-04-19 2002-04-19 Derives de n-[phenyl(piperidin-2-yl)methyl)benzamide, leur preparation et leur application en therapeutique

Publications (2)

Publication Number Publication Date
CN1662497A CN1662497A (zh) 2005-08-31
CN100482646C true CN100482646C (zh) 2009-04-29

Family

ID=28686193

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB038140063A Expired - Fee Related CN100482646C (zh) 2002-04-19 2003-04-17 N-[苯基(哌啶-2-基)甲基]苯甲酰胺衍生物,其制备方法及其在治疗中的应用

Country Status (35)

Country Link
US (2) US7326722B2 (https=)
EP (1) EP1499589B1 (https=)
JP (1) JP4597532B2 (https=)
KR (2) KR20040103973A (https=)
CN (1) CN100482646C (https=)
AR (1) AR039413A1 (https=)
AT (1) ATE361279T1 (https=)
AU (1) AU2003262420B2 (https=)
BR (1) BR0309397A (https=)
CA (1) CA2481461C (https=)
CO (1) CO5631432A2 (https=)
CY (1) CY1108025T1 (https=)
DE (1) DE60313602T2 (https=)
DK (1) DK1499589T3 (https=)
EA (1) EA007225B1 (https=)
EC (1) ECSP045369A (https=)
ES (1) ES2286444T3 (https=)
FR (1) FR2838739B1 (https=)
HR (1) HRP20040977B1 (https=)
IL (2) IL164400A0 (https=)
IS (1) IS2540B (https=)
MA (1) MA27192A1 (https=)
ME (1) MEP25608A (https=)
MX (1) MXPA04010326A (https=)
NO (1) NO329065B1 (https=)
NZ (1) NZ536015A (https=)
PL (1) PL373195A1 (https=)
PT (1) PT1499589E (https=)
RS (1) RS51888B (https=)
SI (1) SI1499589T1 (https=)
TN (1) TNSN04208A1 (https=)
TW (1) TWI306402B (https=)
UA (1) UA78025C2 (https=)
WO (1) WO2003089411A1 (https=)
ZA (1) ZA200408154B (https=)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2842804B1 (fr) 2002-07-29 2004-09-03 Sanofi Synthelabo Derives de n-[phenyl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
FR2861073B1 (fr) * 2003-10-17 2006-01-06 Sanofi Synthelabo Derives de n-[heteroaryl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
FR2861071B1 (fr) * 2003-10-17 2006-01-06 Sanofi Synthelabo Derives de n-[phenyl(alkylpiperidin-2-yl) methyl]benzamide, leur prepartation et leur application en therapeutique
FR2861074B1 (fr) * 2003-10-17 2006-04-07 Sanofi Synthelabo Derives de n-[phenyl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
FR2861070B1 (fr) * 2003-10-17 2006-01-06 Sanofi Synthelabo Derives de n-[phenyl(pyrrolidin-2-yl)methyl]benzamide et n-[(azepan-2-yl)phenylmethyl]benzamide, leur preparation et leur application en therapeutique
WO2005044810A1 (en) * 2003-10-30 2005-05-19 Janssen Pharmaceutica, N.V. Glyt2 modulators
US20050209317A1 (en) * 2004-03-22 2005-09-22 Apkarian A V Method and compositions for treatment of chronic neuropathic pain
ES2520015T3 (es) * 2005-04-08 2014-11-11 Pfizer Products Inc. [3.1.0]Heteroaril amidas bicíclicas como inhibidores de transporte de glicina de tipo 1
JP2009179562A (ja) * 2006-08-11 2009-08-13 Taisho Pharmaceutical Co Ltd グリシントランスポーター阻害剤
FR2917735B1 (fr) * 2007-06-21 2009-09-04 Sanofi Aventis Sa Nouveaux indazoles substitutes, leur preparation et leur utilisation en therapeutique
TW200911808A (en) * 2007-07-23 2009-03-16 Astrazeneca Ab Novel compounds
MX2009014235A (es) 2007-08-22 2010-04-27 Abbott Gmbh & Co Kg 4-bencilaminoquinolonas, composiciones farmaceuticas que las contiene y su uso.
MX2010010773A (es) 2008-04-01 2011-04-11 Abbott Gmbh & Co Kg Tetrahidroisoquinolinas, composiciones farmaceuticas que las contienen y su uso en terapia.
WO2010087761A1 (en) * 2009-01-28 2010-08-05 Astrazeneca Ab 2-aza-bicyclo[2.2.2]octane compounds and uses thereof
AR075442A1 (es) 2009-02-16 2011-03-30 Abbott Gmbh & Co Kg Derivados de aminotetralina, composiciones farmaceuticas que las contienen y sus usos en terapia
TW201038569A (en) 2009-02-16 2010-11-01 Abbott Gmbh & Co Kg Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy
JP5618047B2 (ja) * 2010-01-29 2014-11-05 国立大学法人千葉大学 ポジトロン断層撮影法およびポジトロン放出化合物
US8883839B2 (en) 2010-08-13 2014-11-11 Abbott Laboratories Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9051280B2 (en) 2010-08-13 2015-06-09 AbbVie Deutschland GmbH & Co. KG Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US8877794B2 (en) 2010-08-13 2014-11-04 Abbott Laboratories Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US8846743B2 (en) 2010-08-13 2014-09-30 Abbott Laboratories Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9045459B2 (en) 2010-08-13 2015-06-02 AbbVie Deutschland GmbH & Co. KG Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9309200B2 (en) 2011-05-12 2016-04-12 AbbVie Deutschland GmbH & Co. KG Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy
EP2723718A1 (en) 2011-06-24 2014-04-30 Amgen Inc. Trpm8 antagonists and their use in treatments
US8710043B2 (en) 2011-06-24 2014-04-29 Amgen Inc. TRPM8 antagonists and their use in treatments
CA2844275A1 (en) 2011-08-05 2013-02-14 AbbVie Deutschland GmbH & Co. KG Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy
MX2014006004A (es) 2011-11-18 2015-04-16 Abbvie Deutschland Derivados de aminobenzociclohepteno, aminotetralina, aminoindano y fenalcilamina n-sustituidas, composiciones farmaceuticas que los contienen, y su uso en terapia.
FR2983197B1 (fr) * 2011-11-29 2014-07-25 Assist Publ Hopitaux De Paris Utilisation de phacetoperane pour traiter un trouble deficit de l'attention hyperactivite
US9365512B2 (en) 2012-02-13 2016-06-14 AbbVie Deutschland GmbH & Co. KG Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy
US8952009B2 (en) 2012-08-06 2015-02-10 Amgen Inc. Chroman derivatives as TRPM8 inhibitors
US9656955B2 (en) 2013-03-15 2017-05-23 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9650334B2 (en) 2013-03-15 2017-05-16 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
CA2924689A1 (en) 2013-10-17 2015-04-23 AbbVie Deutschland GmbH & Co. KG Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy
MX2016004934A (es) 2013-10-17 2016-12-20 Abbvie Deutschland Derivados de aminotetralina y aminoindano, composiciones farmaceuticas que los contienen, y su uso en terapia.
US9550754B2 (en) 2014-09-11 2017-01-24 AbbVie Deutschland GmbH & Co. KG 4,5-dihydropyrazole derivatives, pharmaceutical compositions containing them, and their use in therapy
US20170143681A1 (en) 2015-11-02 2017-05-25 Apkarian Technologies Llc Methods and compositions for treating pain
FR3045044B1 (fr) * 2015-12-11 2019-04-19 Liphatech Composition et appat rodonticide comprenant du flocoumafene, procede de lutte contre des rongeurs cibles nuisibles

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0499995A2 (en) * 1991-02-20 1992-08-26 Nisshin Flour Milling Co., Ltd. Piperidine derivatives
US5254569A (en) * 1991-01-14 1993-10-19 The Du Pont Merck Pharmaceutical Company (Amidomethyl)nitrogen heterocyclic analgesics
CN1291984A (zh) * 1998-03-06 2001-04-18 詹森药业有限公司 甘氨酸传输抑制剂

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5524569A (en) * 1995-03-20 1996-06-11 Rich; William A. Anchor cover
AU2001254546A1 (en) * 2000-04-20 2001-11-07 Nps Allelix Corp. Aminopiperidines

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5254569A (en) * 1991-01-14 1993-10-19 The Du Pont Merck Pharmaceutical Company (Amidomethyl)nitrogen heterocyclic analgesics
EP0499995A2 (en) * 1991-02-20 1992-08-26 Nisshin Flour Milling Co., Ltd. Piperidine derivatives
CN1291984A (zh) * 1998-03-06 2001-04-18 詹森药业有限公司 甘氨酸传输抑制剂

Also Published As

Publication number Publication date
HRP20040977A2 (en) 2004-12-31
US20050159450A1 (en) 2005-07-21
CO5631432A2 (es) 2006-04-28
ES2286444T3 (es) 2007-12-01
AU2003262420A1 (en) 2003-11-03
NO329065B1 (no) 2010-08-09
WO2003089411A1 (fr) 2003-10-30
TW200306830A (en) 2003-12-01
MXPA04010326A (es) 2005-07-05
CA2481461C (en) 2010-01-12
IL164400A0 (en) 2005-12-18
HRP20040977B1 (hr) 2008-04-30
DK1499589T3 (da) 2007-09-10
IS2540B (is) 2009-09-15
SI1499589T1 (sl) 2007-10-31
EA007225B1 (ru) 2006-08-25
IS7479A (is) 2004-09-30
EA200401172A1 (ru) 2005-04-28
IL164400A (en) 2010-11-30
US7326722B2 (en) 2008-02-05
ECSP045369A (es) 2005-03-10
CA2481461A1 (en) 2003-10-30
NZ536015A (en) 2006-11-30
US20070197601A1 (en) 2007-08-23
ZA200408154B (en) 2005-10-10
AR039413A1 (es) 2005-02-16
JP2005527593A (ja) 2005-09-15
KR20040103973A (ko) 2004-12-09
EP1499589B1 (fr) 2007-05-02
RS51888B (sr) 2012-02-29
PL373195A1 (en) 2005-08-22
NO20044388L (no) 2005-01-19
DE60313602T2 (de) 2008-01-10
JP4597532B2 (ja) 2010-12-15
KR101019313B1 (ko) 2011-03-07
BR0309397A (pt) 2005-03-01
KR20080075236A (ko) 2008-08-14
TNSN04208A1 (fr) 2007-03-12
RS91404A (sr) 2007-02-05
TWI306402B (en) 2009-02-21
EP1499589A1 (fr) 2005-01-26
MA27192A1 (fr) 2005-01-03
PT1499589E (pt) 2007-08-10
DE60313602D1 (de) 2007-06-14
UA78025C2 (en) 2007-02-15
FR2838739B1 (fr) 2004-05-28
MEP25608A (en) 2010-06-10
AU2003262420B2 (en) 2009-02-19
ATE361279T1 (de) 2007-05-15
FR2838739A1 (fr) 2003-10-24
CN1662497A (zh) 2005-08-31
CY1108025T1 (el) 2013-09-04

Similar Documents

Publication Publication Date Title
CN100482646C (zh) N-[苯基(哌啶-2-基)甲基]苯甲酰胺衍生物,其制备方法及其在治疗中的应用
JP4488891B2 (ja) Ｎ−［フェニル（ピペリジン−２−イル）メチル］ベンズアミド誘導体、その製造法、およびその治療用途
AU2004281214B2 (en) Derivatives of N-``phenyl(piperidine-2-yl) methyl benzamide, preparation method thereof and applications of same in therapeutics
US7790753B2 (en) Derivatives of N-[phenyl(alkylpiperidine-2-yl)methyl]benzamide, preparation method thereof and application of same in therapeutics
US20060223886A1 (en) Derivatives of N-[heteroaryl(piperidine-2-yl) methyl]benzamide, preparation method thereof and application of same in therapeutics
JP2006513151A (ja) ４−アミノピペリジン誘導体、その製造方法及び医薬品としての使用
CN101801927A (zh) 作为nk3受体拮抗剂的哌啶衍生物
MXPA06004268A (en) Derivatives of n-``phenyl(piperidine-2-yl) methyl benzamide, preparation method thereof and applications of same in therapeutics
CN102388049A (zh) N-[(2-氮杂双环[2.1.1]己-1-基)-芳基-甲基]-苯甲酰胺衍生物、其制备及其治疗用途
HK1098143A (en) Derivatives of n-"phenyl(piperidine-2-yl) methyl benzamide, preparation method thereof and applications of same in therapeutics
JPWO2001070689A1 (ja) オピオイドδ受容体作用薬として有用なジフェニルアルキルアミン誘導体
CN102388050A (zh) N-[(6-氮杂二环[3.2.1]辛-1-基)芳基甲基]苯甲酰胺衍生物、其制备方法以及其治疗用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20090429

Termination date: 20120417